Poor
Needs Review
Patient Risk:
Moderate
Summary
The response correctly identifies atorvastatin's HMG-CoA reductase inhibition and its myopathy/rhabdomyolysis risks. However, the supplied label does not address soy, so its multiple confident claims about soy interactions, efficacy, safety, and timing are unsupported by the label.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a statin that lowers cholesterol by inhibiting HMG-CoA reductase.
Sections 12.1 and 5.1 identify LIPITOR as an HMG-CoA reductase inhibitor and atorvastatin as a statin.
Myopathy and rhabdomyolysis are risks of Lipitor.
Section 5.1 states that atorvastatin can cause myopathy and reports rare cases of rhabdomyolysis with LIPITOR.
Unsupported Statements
No established negative interaction exists between atorvastatin and soy protein.
The supplied label does not discuss soy protein; its silence does not establish that no interaction exists.
Soy protein does not significantly alter atorvastatin pharmacokinetics.
The supplied label does not report a study of soy protein with atorvastatin.
Soy protein does not significantly alter atorvastatin efficacy.
The supplied label does not evaluate soy protein coadministration or its effect on atorvastatin efficacy.
Soy protein may modestly lower LDL cholesterol on its own.
The supplied label does not discuss soy protein or its effects on LDL cholesterol.
A 2019 meta-analysis found that soy protein reduced total cholesterol by 3–4% and LDL cholesterol by 3–5% in people with hypercholesterolemia.
The supplied label does not mention this meta-analysis or these soy-related results.
No reports indicate that soy protein reduces statin potency.
The supplied label does not discuss soy protein or reports about its effects on statin potency.
Animal studies suggest that soy isoflavones do not inhibit atorvastatin metabolism via CYP3A4.
The label discusses atorvastatin metabolism involving CYP3A4 but does not address soy isoflavones or these animal studies.
Limited direct trials of atorvastatin and soy protein show no adverse interactions.
The supplied label describes no direct trials of atorvastatin with soy protein.
A small 2008 human study found that combining soy protein with simvastatin enhanced cholesterol reduction without safety issues.
The supplied label does not mention simvastatin or this study.
Drug interaction databases list no warnings for soy protein with atorvastatin.
The label does not report the contents of drug interaction databases or address soy protein.
Soy protein could amplify lipid-lowering for people taking statins without adding risk.
The label does not evaluate soy protein's effects on lipid lowering or safety when combined with statins.
There is no evidence linking soy to Lipitor-associated myopathy or rhabdomyolysis.
The label describes myopathy and rhabdomyolysis risks but does not address soy; it therefore cannot establish the absence of a soy-related link.
Whole soy foods pose a lower interaction risk with Lipitor than isolated soy protein products.
The supplied label does not compare whole soy foods with isolated soy protein products.
Soy does not need to be separated from Lipitor dosing.
Although Section 2.1 permits LIPITOR administration at any time of day, with or without food, the label does not address timing relative to soy.
Contradictions
Important Omissions
The response should make clear that the supplied label does not evaluate soy protein with atorvastatin, so the label cannot substantiate claims about interaction risk, effects, or timing.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
The response gives reassuring soy-related safety and interaction claims that are not established by the supplied label. The label does identify myopathy and rhabdomyolysis as LIPITOR risks, but it does not assess whether soy affects those risks.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Needs Review
Primary Issue
Multiple soy-related interaction, efficacy, safety, and dosing-timing claims are not supported by the supplied prescribing information.
Suggested Improvement
Distinguish information established by the label from claims it does not address; avoid presenting the absence of soy information in the label as evidence that there is no interaction or added risk.